Last reviewed · How we verify
NCT03868436: ADVANCE-ED
PENTHROX™ in the Canadian Emergency Department (ED)
Phase 4 trial testing Methoxyflurane 3mL in Pain, Acute in 99 participants. Completed in 8 September 2020.
30 March 2020
Quick facts
| Lead sponsor | Purdue Pharma, Canada |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 99 |
| Start date | 8 April 2019 |
| Primary completion | 30 March 2020 |
| Estimated completion | 8 September 2020 |
| Sites | 6 locations across Canada |
Drugs / interventions tested
- Methoxyflurane 3mL — full drug profile →
Conditions studied
- Pain, Acute — all drugs for Pain, Acute →
Sponsor
Purdue Pharma, Canada — full company profile →
Who can join
18 and older, any sex, with Pain, Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This Canadian, multi-centre, prospective, real world study is designed to evaluate the effectiveness of low dose methoxyflurane (MEOF) (PENTHROX™) for the treatment of moderate to severe pain associated with trauma in the Canadian ED.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03868436
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pain, Acute
Currently open trials in the same condition.
- NCT07249827 — A Randomized Comparison Between 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg of Perineural Dexmedetomidine for Ultrasound-Guid · Phase 2 · recruiting
- NCT07053774 — Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain · Phase 2 · recruiting
- NCT07009951 — Impact of Virtual Reality in Cardiac Electrophysiology · recruiting
- NCT06960317 — Empathy Through Pain Control: Lidocaine Paracervical Block for IUD Placements · NA · recruiting
- NCT06754657 — CORA-Q15: Continuous vs. Single-injection Interscalene Block on QoR-15 in Outpatient Rotator Cuff Surgery · Phase 4 · recruiting
Other Purdue Pharma, Canada trials
Trials by the same sponsor.
- NCT04152629 — Real World Evidence of the Efficacy and Safety of FOQUEST · Phase 4 · completed
- NCT03649230 — Observational Study on the Use of Akynzeo® in Patients Receiving HEC · completed
- NCT03618030 — PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) · Phase 3 · completed
- NCT03172481 — PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03868436 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Purdue Pharma, Canada
- Last refreshed: 16 September 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03868436.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing